There is now a sound base for training and doctors of high calibre with a strong backing in clinical oncology and research are now available to fill new posts in Medical Oncology. Such posts are undoubtedly needed in view of the increasingly important role of systemic treatment in improving the survival of patients with cancer. The number of posts must be tailored to the relative work load and research requirements in chemotherapy, radiotherapy and surgery. My own view is that, initially, such posts should be introduced in close association with existing Departments of Radiotherapy in our major cities and, following this, physicians with a special interest and training in Medical Oncology could be appointed to local district general hospitals to improve chemotherapy services in the region. This is the pattern of development which is being encouraged in the north-west of England.
My talk concerns new approaches being made in the management of patients with non-Hodgkin's lymphoma (NHL) of highgrade pathology (i.e. those composed of large cells arranged in a diffuse pattern) and I will colour my presentation with data from studies being undertaken in Manchester, in both the clinic and the laboratory.
A recent publication of the Office of Population Censuses and Surveys (1980) is rather disturbing. The 5-year survival of patients with NHL in England and Wales has not improved significantly over a period of almost 10 years, in spite of notable improvements in chemotherapy (Table I) . The overall 5-year survival of about 300/o must be considered in the context of an expected 50%o in the subgroup with low-grade histology treated in a palliative manner with low-dose single-agent chemotherapy and radiotherapy. This means that patients with high-grade histology are faring badly, and the object of the first part of my talk is to suggest that the new approaches now being adopted for this unfavourable group of patients in special centres should lead to an improvement in survival in the country as a whole. In NHL patients careful documentation of the extent of disease is important in determining the part to be played by local treatment such as surgery or radiotherapy, and is necessary in defining the role of chemotherapy. Although some patients can be cured by radiotherapy or surgery alone, not more than 10% of all patients achieve long-term relapse-free survival following local treatment alone. Chemotherapy, therefore, has a major role in these diseases.
CHEMOTHERAPY FOR GENERALIZED DISEASE
Combination chemotherapy used intermittently has proved to be of greater value than single-agent chemotherapy in patients with high-grade lymphomas and complete remissions are now obtained in 40-70% of treated patients. Several retrospective studies have been reported recently showing an advantage in using Adriamycin-containing regimens in terms of rate of complete remission and relapsefree survival (Cabanillas et al., 1978; Johnson et al., 1979; MacKintosh et al., 1980) . The role of cyclophosphamide in the induction programme is less clear, with at least one report showing an advantage to an Adriamycin-containing combination without cyclophosphamide (Bodey & Rodriguez, 1978) .
The duration of relapse-free survival after induction of complete remission is dependent upon the histological subtype, with those classified as diffuse "histiocytic" lymphomas using the Rappaport classification having long-term relapsefree survival compared with a continuing relapse pattern for those classified as diffuse poorly differentiated lymphocytic (Schein et al., 1975) .
The group at the National Cancer Institute, Bethesda, reported a complete remission rate in 56 patients with diffuse histiocytic lymphoma of 47%. Although the overall median survival was poor (14 months), one third of the patients survived in complete remission at 5 years.
Very few patients relapsed if they were still in remission one year after induction of remission using combination chemotherapy, and the suggestion was made that these patients could well be cured (Fisher et al., 1977) .
Most reports have involved combination chemotherapy given intermittently, but the poor median survival illustrates the propensity for early relapse and death in more than half the patients. The recognition that treatment failure frequently occurs early in the first few months of induction chemotherapy, with failure to achieve complete remission and a tendency to relapse between courses, led to the introduction of a more continuous form of chemotherapy using combined chemotherapy involving a weekly schedule at St Bartholomew's Hospital in 1972. The combination was similar to that successful in treating acute lymphoblastic leukaemia, and involved vincristine, prednisolone, Adriamycin and L-asparaginase (OPAL). We recently reported the results of treating a small number of patients with diffuse histiocytic lymphoma using this approach (Lister et al., 1978) . All 10 patients with Stage III disease and 6/11 patients with Stage IV disease achieved a complete remission, and preliminary results showed promising long-term relapse-free survival.
The Manchester Lymphoma Group has addressed the problem of early failure using a similar approach (Blackledge et al., 1980b) . More than 18 months of further 418 follow-up is now available for patients in this study, and updated results are included here. Induction chemotherapy consisted of prednisolone (40 mg orally daily for 6 weeks), vincristine (2 mg weekly i.v. for 6 weeks) and 3 i.v. injections of Adriamycin (50 mg/M2) at 2-weekly intervals (VAP). In addition, local radiotherapy was given to areas of residual or previously bulky disease in an attempt to reduce the relapse rate in these areas.
Subsequent chemotherapy involved a 2-year programme of continuing therapy using cyclophosphamide (200 mg/M2), methotrexate (10 mg/Mi2 orally weekly) and 6-mercaptopurine (50 mg/M2 orally daily). The doses were tailored to maintain the white blood count 3000-3500/pl. probability of achieving a complete remission revealed 5 factors of independent significance (Table II) . Increased serum alkaline phosphatase, increasing age, presence of B symptoms, marrow involvemeiit and male sex were all associated with a significant reduction in the probability of a complete remission. There was no difference in complete-remission rate between patients with diffuse histiocytic and diffuse poorly-differentiated lymphocytic lymphoma. The median duration of follow-up was 4 years, and the overall survival in the 107 patients is shown in Fig. 1 (Fig. 3 ).
There was a statistically significant difference in survival (P=0 001) and relapse-free survival (P = 0.01) in patients who received bulk radiotherapy after induction chemotherapy. The improved AMANAGEMENT OF NON-HODGKIN'S LYMPHOMIA surxvival seen in patients receiving radiotherapy was still significant after adjustment for the effects of the 4 pretreatment variables in Table III , but this treatment was not randomized, and the data must be interpreted with caution. The results suggest that a prospective randomized study of radiotherapy following induction chemotherapy could be well worthwhile.
Skarin and his colleagues from Boston (Skarin et al., 1980) have recently reported data on another frequent chemotherapy schedule which lends support to the suggestion that this approach may lead to improved complete remission rates and long-term relapse-free survival. A group from Seattle (Sullivan et al., 1979) have also suggested that radiotherapy could have a useful role following initial chemotherapy and one third of the patients completed their remission using radiotherapy in their series. The radiotherapy given included whole-body irradiation if the marrow was involved, and this approach, which was more aggressive than our own, may have contributed to the higher complete-remission rate. The contribution of these different forms of radiotherapy to the improved survival in patients with diffuse lymphomas deserves further study under controlled conditions.
The appreciation that patients with some forms of diffuse pathology have a continuous relapsing pattern and poor survival in spite of a high apparent initial remission rate is disappointing. A more intensive approach using combined chemotherapy and radiotherapy may lead to further improvement in survival, but this remains to be tested. In my view, a radical approach following the induction of remission is now required. In contrast with diffuse histiocytic lymphoma, where high-dose irradiation frequently fails to control local disease, recurrences in the irradiated area after moderate-dose radiotherapy for diffuse lymphocvtic or lymphoblastic disease are less common (Fuks & Kaplan, 1]975). Low-dose whole-body irradiation (1-3 Gy) has proved of some valuie in the control of lymphocytic lymphomas, though it is no better than chemotherapy, and myelodepression contributes to difficulties in later treatment (Johnson et al., 1978) . For these reasons, an approach using combined intensive combination chemotherapy with higherdose whole-body irradiation (1I Gy) for selected patients with diffuse poorly differentiated lymphocytic or lymphoblastic forms of lymphoma is now worth studying. The marrow is frequently involved in such patients, and homologous marrow transplantation would be required. The promising results in patients with acute leukaemia using this approach provide a good argument for studying this new method of treatment in patients with diffuse lymphoma in whom a, complete remission has been achieved.
Central nervous system (CONS) involvement
Involvement of the CNS is a well known complication in patients with lymphoma. The reported incidence varies from < 5o to > 25%, with the highest incidence in patients with diffuse histology. However, few patients are likely to benefit from prophylactic treatment of the CNS, since most patients in whom CNS involvement develops present at a time of advancing or uncontrolled disease in other areas (Young et al., 1979) . In addition, the routine prophylaxis may compromise the ability to deliver adequate chemotherapy for cure. For these reasons, the careful selection of patients at high risk is mandatory if prophylaxis is to be tested. Further study of this topic is also warranted because the choice of effective therapy for CNS disease is in doubt. Our policy in the Manchester Lymphoma Group is to avoid prophylactic treatment of the CNS until further data accrue on the incidence of CNS relapse in patients who are otherwise in complete remission.
CHEMOTHERAPY FOR LOCALIZED DISEASE
Localized or regional radiotherapy may produce prolonged relapse-free survival in about half the patients with lymphomas Kaplan, 1975) . Nearly all relapses, however, occur by wide dissemination, and chemotherapy therefore has an important role in this context in preventing the growth of tumour in these disseminated sites and the recurrence of tumour in areas treated previously with radiotherapy.
The Milan group have reported their 5-year follow-up data of a controlled randomized trial of combination chemotherapy used as an adjuvant after radiotherapy for pathological stage (PS) I/II NHL (Monfardini et al., 1979) . After treatment with regional radiotherapy, patients in complete remission were randomized to receive either no further therapy or 6 cycles of CVP (cyclophosphamide, vincristine and prednisolone). A total of 96 patients were evaluable. At 5 years from completion of irradiation, the relapse-free survival was 46% after radiotherapy and 72% after radiotherapy with CVP (P= 0.005). The corresponding findings for the overall survival calculated from the beginning of irradiation were 55% and 83% respectively (P= 0.03). The favourable effect of adjuvant chemotherapy on relapse-free survival was statistically significant, irrespective of stage and clinical presentation in the subgroup with diffuse histology which represented more than 70% of the entire series. In contradistinction, patients with nodular histology showed no improved relapse-free survival after 6 cycles of CVP. In patients relapsing after radiotherapy alone, salvage therapy failed to induce a high incidence of second durable remissions. This study is important in that 98% of the patients had pathological staging (26% by laparoscopy and 74% by laparotomy). Glatstein and his colleagues from Stanford (Glatstein et al., 1977) reported a study in which they failed to observe an improvement in overall survival or relapse-free survival in PS 1/11 patients with high-grade histology using total nodal irradiation with CAT (cytosine arabinoside, Adriamycin and thioguanine) for diffuse histiocytic lymphoma, and CVP for all other histologies. This was also true for the study reported by Panahon et al. (1977) . The reason for these different results may well be related to the differences in the radiotherapy rather than the chemotherapy used in the studies.
A study from Stockholm supports the findings of the Milan group (Landberg et al., 1979) . Fifty five patients with nodular or diffuse lymphoma of CS I/II were randomized for 9 cycles of CVP after radiotherapy; the relapse-free survival at 30 months was 41% for patients without and 86% for patients with adjuvant chemotherapy (P=0 02). Survival was the same for both treatment arms, being 90% at 30 months. Analysis of the subgroups showed that adjuvant chemotherapy significantly prolonged the relapse-free survival in diffuse histiocytic lymphoma, but there were only 20 evaluable patients in this group. This study suffers from the defect of small numbers of patients and short follow-up.
The Manchester Lymphoma Group is conducting a study comparing the effects of two forms of combination chemotherapy as an adjuvant after radiotherapy for nodal stages I/II disease. . There were 104 patients with full details of the surgery obtained. Although the median survival was only 15 months, 35% were alive and well at 10 years. The tumour type (histology, site and whether single or multiple) extent of lymph-node involvement and the presence of local extension to adjacent organs, perforation with peritonitis or distant metastases were of considerable prognostic importance. The Ann Arbor staging classification was inadequate for this group of patients, and a new staging system for gastrointestinal lymphoma has been proposed, which has prognostic significance and can be used to select appropriate poor prognostic groups for chemotherapy. It was clear from the data that patients fared much better if tumour excision was complete. Each of the patients had initial surgery involving laparotomy, and all apparent tumour was removed in 41 patients. This included removal of locally involved nodal masses and tumour which had spread to adjacent tissues. The group had a much better survival than the remainder with either incomplete tumour removal or merely tumour biopsies (P=0.0005). Of the 49 patients who had complete removal of the tumour, only 11 had a single tumour confined to the gut; all the others had either local nodes involved or spread to adjacent tissues. Considering only Stage II patients with disease extending outside the gastrointestinal tract, there was still a highly significant difference between the patients with complete and incomplete removal of the tumour (P = 0.004). Cure is a distinct possibility after surgery alone for patients with gastrointestinal lymphoma, but tumour removal must be complete. Other groups with incomplete removal have a poor survival, in spite of the addition of radiotherapy, and early chemotherapy is then of recognizable value.
Unlike most forms of nodal lymphoma, Wt'hole-body scanning with computed tomography (CT) Surgical staging is not recommended for most patients presenting with NHL, since laparotomy is potentially dangerous and generalized disease can usually be documented by conventional clinical staging. Treatment decisions are usually based on staging procedures which avoid laparotomy in this group of patients. CT has enabled a more accurate documentation of the pattern of disease at presentation than could be achieved by conventional clinical staging alone, and therefore plays an important part in initial staging. Its advantages over abdominal lymphography have previously been documented . In Manchester, whole-body CT has replaced abdominal lymphography in lymphoma patients.
At presentation and clinical relapse, CT scanning detects unsuspected disease in a high proportion of patients with lymphoma, and has an important influence on treatment policy. The evaluation of response to chemotherapy and the detection It has been observed in rats with Roser leukaemia that coeliac nodes enlarge by a factor averaging over 500 whereas superficial cervical lymph nodes undergo only a 4-fold enlargement. Further study has shown that preferential migration of lymphoma cells from the blood to the coeliac node in this condition contributed to the unusual pattern of distribution (Ford, 1978) . Lymphoid blast cells arising from stimulation with an allogeneic graft, however, also show a predilection for the coeliac node, but in this situation the node does not become excessively large, since the cells have a short transit time (Smith et al., 1980) . Preferential migration and alterations in transit time may therefore be of major importance in determining a 425 pattern of disease distribution. Ford has suggested that the high incidence of coeliac-node involvement in Hodgkin's disease could be explained by migration of tumour cells via the blood to the liver and thence to the coeliac node, rather than by retrograde lymphatic spread. In addition, the use of lymphoma lines in experimental systems has indicated that there may be differences in the high endothelial venules of different tissues and organs through which lymphocytes migrate (Butcher & Weissman, 1980 (Rannie et al., 1977a,b; Chisholm et at., 1978; Issekutz et at., 1980; Sparshott et al., in preparation). Lavender et al. (1977) showed that external imaging of 11lIn-labelled lymphocytes was possible in man, and following studies in Manchester, the method has an established value in following the traffic of normal lymphocytes and their malignant counterparts in man (Wagstaff et at., 1981a,b) .
Indium-ill oxine is a lipid-soluble complex with a high labelling efficiency, a low elution rate, and produces Auger electrons which allow autoradiography.
The gamma emission spectrum is ideal for external imaging on a conventional gamma camera. By using a combination of gamma-camera imaging and surface-probe counting, it is possible to assess the changing patterns of distribution of lymphocytes in man following re-injection.
When the lymphocyte population from control subjects (predominantly T cells) is labelled and re-injected, the number of labelled cells in the blood falls during the first 4 h. The cells leaving the blood mainly accumulate in the spleen, which shows increased imaging during this initial period. There is an increase in labelled cells in the blood during the 4-24 h period during which the splenic activity falls by about 40%. During time of small lymphocytes through the human spleen seems to be similar to that in small experimental animals, and preliminary data suggest that the traffic into and out of lymph nodes also approximates to that found in experimental animal systems. The data are consistent with the T cells leaving the blood and entering the spleen after re-injection. After 4-6 h, they would have traversed the splenic white pulp and reappeared in the blood, causing the observed secondary rise in the bloodclearance curves (Fig. 4) . (Wagstaff et al., unpublished) . Unlike controls, CLL patients showed no evidence of a rise oflabelled cells in the blood in the 4-24h period. Patients with CLL or lymphomas with B lymphocytosis showed a continuous rise in uptake by the spleen between 4 and 24 h, with a fall between 24 and 48 h. This contrasts with the fall in counts over the spleen 4 h after the reinjection of normal lymphocytes into control subjects. The more continuous removal of labelled B cells from the blood in the patients with B-cell malignancy sug- Hours After Re-Injection Fie(1. 5.-Blood-clearance cur.-es, together with spleen and liver uptake of indiumoxine-labelled lymphocytes from a patient with chronic lymphocytic leukaemia. Unlike normal lymplhocytes (Fig. 4) there is no secondary increase of labelled cell sin the blood following their rapid clearance, an1(l thle piobe couints over ths spleen are relatiVely constant over 48 hi.
gests that even at 48 h, few labelled cells have returned to the blood after primary localization. The distribution to heavily involved organs such as the liver and marrow in these patients has also been observed. Marrow imaging is more intense in CLL patients than in control subjects.
It does not follow that the kinetics of migration of these cells is related to their malignancy, however, since it is known that B cells in animals have a more prolonged migration pattern than T cells (Ford, 1975 review). T lymphocytes generally recirculate much more rapidly than B cells, though they leave the blood by crossing the post-capillary venules in lymph nodes at the same rate. T cells have a mean transit time of 5-6 h through the spleen, and 16-18 h through lymph nodes, compared with B cells which have not left the spleen in significant numbers by 24 h after re-injection and have a mean transit time of 30-36 h through the lymph nodes. The observed difference in distribution seen in patients with lymphoid-cell maliglignancy could be explained by the proportion of T and B cells used, since T cells migrate more rapidly through the spleen, the major site of primary localization of lymphocytes. The subsequent rise and plateau seen under normal circumstances could be due to the reappearance of labelled T cells in the blood that have passed through the spleen. The question of whether CLL B lymphocytes have migratory properties similar to normal B cells needs to be answered. This should be possible with further work using the llln-oxine labelled lymphocytes.
Other subsets of lymphocytes within the blood are known to have different patterns of migration in experimental systems, and gut, lung and salivary lymphoid tissue may well have characteristic migratory patterns. Further work on this important new concept, using experimental animals, would be well worthwhile.
Using l1lln oxine-labelled cells, it can be shown that some patients with other malignancies have an extremely large flux of lymphocytes through tumour tissue. taken up by the mediastinal tumour, and visualization of the enlarged nodes may occur as early as 30 min after re-injection. Such a flux of lymphocytes may be an important mechanism enabling contact to be made between tumour tissue and the reactive lymphoid cells which are known to be in the blood of patients with Hodgkin's disease (Crowther et al., 1969a,b) . These cells are similar to those seen in the blood after antigenic stimulation.
Although an antigenic stimulus promotes lymphocyte migration, antigen specificity does not appear to contribute to the initial homing. Lymphocyte migration is, however, facilitated by an increase in local blood flow, and this appears to be an important mechanism for bringing antigen-specific lymphoid cells into appropriate contact with foreign material at sites of inflammation (Hay et al., 1980 The method of monoclonal antibody production using mouse hybridomas (Kohler & Milstein, 1975 ) is already proving of value, in addition to the more generally available techniques for characterizing cell-surface phenotypes within the lymphoid malignancies. The biochemical features of the antigenic determinants reacting with monoclonal antibodies can now be investigated, and this most important area of research is now open. Monoclonal antibodies may be directed against specific oligosaccharide sequences, and can be used to dissect the chemistry of the cell-surface glycoproteins. Preliminary results suggest that the technique is of importance in determining the immunological phenotype of patients with diffuse large-cell lymphoma, and this may be helpful in defining groups with different survival prospects (Warnke et al., 1980) . Clearly, prospective studies involving these new techniques in untreated patients are likely to lead to a better understanding of the biology of these tumours, but the prognostic weight of each parameter must be measured against other known prognostic features, using multi-variate analysis. An approach has already been made to evaluate enzyme and membrane marker properties of leukaemia cells using multi-parameter analysis (Janossy et al., 1980 (Garrett et at., 1979; Ault et al., 1979) . Abnormalities can be detected in the presence of a normal white cell count and differential using anti-light-chain sera, but interpretation is dependent on the ratio of Kappa: Lambda bearing cells. Other techniques, such as the detection of colchicine-sensitive lymphoid cells in the peripheral blood may also be helpful in this regard (Thomson et al., 1972; Scarffe et al., 1980) . These methods, however, are not the only ones available for studying the composition of the plasma membrane in single cells. A method of current interest to our group in Manchester involves a study of the biochemistry of the lymphoid cell surface using plant-lectin binding assessed by flow cytometry. A large number of workers are contributing to the success of these studies, but particular mention must be made of Dr G. Blackledge who conducted the flow-cytometric studies and Dr J. Gallagher who provided the necessary expertise in glycoprotein and lectin chemistry. The immunological studies were in collaboration with Dr B. Vose (Department of Immunology, Paterson Laboratories).
Lectins can be bound to fluorescein isothiocyanate, and the amount attaching to the plasma membrane of single cells can be determined by measuring the emission of fluorescence from each cell in flow cytometry. Differences in lectin binding between cells within a separated population may be investigated using this method. Flow cytometry involves the measurement of different properties of cells passing singly at high speed through a beam of light (Kamentsky et al., 1965) . Light scattering of the beam (related to cell size) and emission of light from a specific fluorescent probe can be assessed (Fig. 7) . The normal lymphocyte population is heterogeneous in lectin-binding properties, whilst the leukaemia-cell population is homogeneous. In the example shown in Fig. 7 , the ALL cells show low concanavalin A (Con A), LCA and WGA binding, whereas the AML cells show much greater binding to these lectins.
Studies of lymphoid cell populations in the peripheral blood from patients with lymphomas (Fig. 8) (Fig. 7) ; several cell populations are visible.
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The abnormal lectin binding of lymphoid cells from the peripheral blood of patients with Hodgkin's disease is of interest (Fig. 7) . Reactive 
